Shape raises $112M B round to grow RNA platform
Company is seeking deals across its rare and neurodegenerative disease pipeline
Amid growing investor interest in RNA modalities, Shape raised a $112 million series B round co-led by Decheng Capital and Breton Capital to advance a suite of programs that target, edit and replace RNA.
While RNA therapeutics are in the spotlight thanks to the success of mRNA vaccines, the modality has been building for years as different forms of using and targeting RNA have been uncovered. ...